Organization (Industry)
Samsung (United States)
ClinicalTrials.gov lists Samsung (United States) as lead sponsor of 1,074 trials, counting the companies grouped under it. Samsung (United States) itself has 2 active development programs and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
Logo Samsung, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Samsung (United States) and 8 companies grouped under it: 1,074 lead-sponsored trials (2 its own, 1,072 in the grouped companies) and 25 legal-entity registrations (12 its own, 13 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (8)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Samsung Medical Center | 1,003 | 1 |
| Kangbuk Samsung Hospital | 63 | 1 |
| Samsung Electronics (South Korea) | 4 | 1 |
| Samsung Changwon Hospital | 1 | 1 |
| Samsung Medison (South Korea) | 1 | 1 |
Showing 5 of 8 member companies.
Disease areas (461)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 67 |
| Breast Neoplasms | 52 |
| Stroke | 51 |
| Lymphoma | 44 |
| Stomach Neoplasms | 43 |
Showing 5 of 461 disease areas.
Trials by start year as sponsor or collaborator (4)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2018 | 1 |
| 2015 | 1 |
| 2014 | 1 |
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (2)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| GV1001 1.12mg | Alzheimer Disease | Phase 3 | 1 |
| GV1001 1.12mg | Dementia | Phase 3 | 1 |
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| GEMCITABINE | 1 |
| "Capecitabine" | 1 |
Journals published in (500)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 40 |
| The New England journal of medicine | 39 |
| JACC. Cardiovascular interventions | 28 |
| Journal of the American College of Cardiology | 19 |
| Journal of the American Heart Association | 19 |
Showing 5 of 500 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2,883 | 797 | 2025-12-30 |
Organization relationships (138)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| National Cancer Center, Korea | Co sponsors trial with | 14 |
| The Catholic University of Korea | Co sponsors trial with | 12 |
| Soonchunhyang University Hospital | Co sponsors trial with | 8 |
| Korea University | Co sponsors trial with | 8 |
| Kyunghee University Medical Center | Co sponsors trial with | 8 |
Showing 5 of 138 relationships.
Latest dated events (4,190)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 4,190 events.
Biomarker capability evidence (4)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACHE | Trial sponsor | Named in trial exclusion criteria |
| ACHE | Trial sponsor | Mentioned in trial text |
| LBP | Trial collaborator | Mentioned in trial text |
| NR0B2 | Trial collaborator | Mentioned in trial text |
Biomarkers this organization publishes on (1,165)
Shown in this order: most publications first.
Showing 5 of 1,165 biomarkers.
On Scientist.com
Samsung (United States) is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with SamSung SDS on Scientist.com
For prices, more details, or to contact SamSung SDS, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.